This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 14 months. Participants will make 6 visits to the clinic including and end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment. Participants that continue treatment with MLN0128 will continue to make additional visits to the clinic once or twice every 4 weeks and the end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment.